13 Nov 2023
// PRESS RELEASE
13 Nov 2023
// PRESS RELEASE
18 Oct 2023
// PRESS RELEASE
About
CPhI WW FrankfurtCPhI WW Frankfurt
Industry Trade Show
Booth #11.0B48
28-30 October, 2025
Industry Trade Show
Attending
29 September-02 October, 2025
Industry Trade Show
Attending
13-14 October, 2025
CONTACT DETAILS
Events
Webinars & Exhibitions
CPhI WW FrankfurtCPhI WW Frankfurt
Industry Trade Show
Booth #11.0B48
28-30 October, 2025
Industry Trade Show
Attending
29 September-02 October, 2025
Industry Trade Show
Attending
13-14 October, 2025
13 Nov 2023
// PRESS RELEASE
13 Nov 2023
// PRESS RELEASE
18 Oct 2023
// PRESS RELEASE
https://www.axplora.com/axplora-appoints-dr-stephan-haitz-as-president-of-its-novasep-cdmo-business-unit/
Registrant Name : Galderma Korea Co., Ltd.
Registration Date : 2024-03-27
Registration Number : 20240327-209-J-1630
Manufacturer Name : FINORGA SAS
Manufacturer Address : Route de Givors Chasse Sur Rhone,38670, France
Registrant Name : Galderma Korea Co., Ltd.
Registration Date : 2023-08-24
Registration Number : 20230824-209-J-1526
Manufacturer Name : FINORGA SAS
Manufacturer Address : route de Givors Chasse Sur Rhone,38670, France
Registrant Name : Novartis Korea Ltd.
Registration Date : 2023-10-10
Registration Number : 20231010-209-J-1549
Manufacturer Name : Finorga SAS
Manufacturer Address : route de Givors, Chasse Sur Rhone, 38670, France
Registrant Name : Galderma Korea Co., Ltd.
Registration Date : 2024-03-27
Registration Number : 20240327-209-J-1630
Manufacturer Name : FINORGA SAS
Manufacturer Address : Route de Givors Chasse Sur Rhone,38670, France
Registrant Name : Galderma Korea Co., Ltd.
Registration Date : 2023-08-24
Registration Number : 20230824-209-J-1526
Manufacturer Name : FINORGA SAS
Manufacturer Address : route de Givors Chasse Sur Rhone,38670, France
Registrant Name : Novartis Korea Ltd.
Registration Date : 2023-10-10
Registration Number : 20231010-209-J-1549
Manufacturer Name : Finorga SAS
Manufacturer Address : route de Givors, Chasse Sur Rhone, 38670, France
Details:
Through the agreement, Novasep will support Celladon’s plans to produce Mydicar, which is being evaluated in the mid-stage clinical trial for the treatment of heart failure.
Lead Product(s): AAV1/SERCA2a,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Mydicar
Study Phase: Phase IIProduct Type: Cell and Gene therapy
Sponsor: Celladon
Deal Size: $5.4 million Upfront Cash: Undisclosed
Deal Type: Agreement December 13, 2023
Lead Product(s) : AAV1/SERCA2a,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Celladon
Deal Size : $5.4 million
Deal Type : Agreement
Novasep Signs €4.7m Biomanufacturing Deal with Biotech
Details : Through the agreement, Novasep will support Celladon’s plans to produce Mydicar, which is being evaluated in the mid-stage clinical trial for the treatment of heart failure.
Product Name : Mydicar
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 13, 2023
Details:
Novasep has successfully optimized and scaled-up the process of Adcitmer® (monomethyl auristatin E-conjugated antibody), McSAF Inside® Oncology’s first-in-class proprietary ADC to treat neuroendocrine cancers.
Lead Product(s): Adcitmer,Inapplicable
Therapeutic Area: Oncology Brand Name: Adcitmer
Study Phase: PreclinicalProduct Type: Antibody-drug Conjugate
Recipient: McSAF
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 18, 2021
Lead Product(s) : Adcitmer,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : McSAF
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Novasep has successfully optimized and scaled-up the process of Adcitmer® (monomethyl auristatin E-conjugated antibody), McSAF Inside® Oncology’s first-in-class proprietary ADC to treat neuroendocrine cancers.
Product Name : Adcitmer
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
November 18, 2021
Details:
The agreement aims for the manufacturing of adeno-associated virus (AAV) vectors, covering the gene therapy program targeting OTOF (OTOF-GT), the gene encoding the otoferlin protein and aims to restore the expression of Otoferlin.
Lead Product(s): OTOF-GT,Inapplicable
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Brand Name: OTOF-GT
Study Phase: PreclinicalProduct Type: Cell and Gene therapy
Sponsor: Sensorion
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 03, 2020
Lead Product(s) : OTOF-GT,Inapplicable
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Sensorion
Deal Size : Undisclosed
Deal Type : Agreement
Sensorion and Novasep Sign Agreement
Details : The agreement aims for the manufacturing of adeno-associated virus (AAV) vectors, covering the gene therapy program targeting OTOF (OTOF-GT), the gene encoding the otoferlin protein and aims to restore the expression of Otoferlin.
Product Name : OTOF-GT
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
November 03, 2020
ABOUT THIS PAGE
Novasep is a supplier offers 2 products (APIs, Excipients or Intermediates).
Find a price of Adapalene bulk offered by Novasep
Find a price of Brinzolamide bulk offered by Novasep